The goal of this project is to develop much-needed tools for study of the kallikrein-kinin (K-K) system. This system appears to play important roles in regulation of blood pressure, inflammation, shock, secretion (renal, salivary, intestinal), blood clotting, the complement system and perhaps central nervous system function. The principal mediators of the K-K system are bradykinin (BK), a nonapeptide, and its homologs kallidin (Lys-BK) and Met-Lys-BK. No specific antagonists exist for these peptides. We hope to develop them. The structure of BK will be modified in ways expected to enhance receptor binding but minimize intrinsic activity. Conformational freedom of the BK molecule will be restricted by incorporation of D-amino acids and substituted amino acids, cyclization of the peptides and attachment of them to macromolecular carriers. BK receptor binding studies will guide peptide design. Peptides will be synthesized by automatic solid phase synthesis, purified by standard techniques and characterized. They will be assayed for agonist and antagonist activity on isolated rat uterus, isolated guinea pig ileum and rat blood pressure. We will continue to study the conformation of BK in solution by CD and NMR spectroscopy. We will attempt to study the conformation of the BK molecule while it is combined with its membrane receptors.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL026284-06
Application #
3338543
Study Section
Bio-Organic and Natural Products Chemistry Study Section (BNP)
Project Start
1980-09-01
Project End
1986-08-31
Budget Start
1985-09-01
Budget End
1986-08-31
Support Year
6
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
Schools of Medicine
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Stewart, John M; Gera, Lajos; Chan, Daniel C et al. (2005) Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists. Peptides 26:1288-91
Stewart, John M; Gera, Lajos; Chan, Daniel C et al. (2004) New lung cancer drugs from bradykinin antagonists. Chest 125:148S
Schroeder, Christian; Breit, Andreas; Boning, Hilke et al. (2003) Changes in amino-terminal portion of human B2 receptor selectively increase efficacy of synthetic ligand HOE 140 but not of cognate ligand bradykinin. Am J Physiol Heart Circ Physiol 284:H1924-32
Stewart, J M (2003) Bradykinin antagonists as anti-cancer agents. Curr Pharm Des 9:2036-42
Stewart, John M; Gera, Lajos; Chan, Daniel C et al. (2002) Bradykinin-related compounds as new drugs for cancer and inflammation. Can J Physiol Pharmacol 80:275-80
Taraseviciene-Stewart, Laimute; Gera, Lajos; Hirth, Peter et al. (2002) A bradykinin antagonist and a caspase inhibitor prevent severe pulmonary hypertension in a rat model. Can J Physiol Pharmacol 80:269-74
Stewart, J M; Gera, L; York, E J et al. (2001) Metabolism-resistant bradykinin antagonists: development and applications. Biol Chem 382:37-41
Reissmann, S; Pineda, F; Vietinghoff, G et al. (2000) Structure activity relationships for bradykinin antagonists on the inhibition of cytokine release and the release of histamine. Peptides 21:527-33
Larrivee, J F; Gera, L; Houle, S et al. (2000) Non-competitive pharmacological antagonism at the rabbit B(1) receptor. Br J Pharmacol 131:885-92
Stewart, J M; Gera, L; York, E J et al. (1999) Bradykinin antagonists: present progress and future prospects. Immunopharmacology 43:155-61

Showing the most recent 10 out of 44 publications